{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:26:19Z","timestamp":1785803179459,"version":"3.56.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> REV1 is a member of the translesion synthesis DNA polymerase Y family. It is an essential player in a variety of DNA replication activities, and perform major roles in the production of both spontaneous and DNA damage-induced mutations. This study aimed to explore the role of REV1 as a prognostic biomarker and its potential function regulating the sensitivity of anti-tumor drugs in various cancers.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We analyzed the impact of REV1 gene alterations on patient prognosis and the impact of different REV1 single nucleotide polymorphisms (SNP) on protein structure and function using multiple online prediction servers. REV1 expression was assessed using data from Oncomine, TCGA, and TIMER database. The correlation between REV1 expression and patient prognosis was performed using the PrognoScan and Kaplan-Meier plotter databases. The IC50 values of anti-cancer drugs were downloaded from the Genomics of Drug Sensitivity in Cancer database and the correlation analyses between REV1 expression and each drug pathway\u2019s IC50 value in different tumor types were conducted.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Progression free survival was longer in REV1 gene altered group comparing to unaltered group [Median progression free survival (PFS), 107.80 vs. 60.89\u00a0months, <jats:italic>p<\/jats:italic> value = 7.062e-3]. REV1 SNP rs183737771 (F427L) was predicted to be deleterious SNP. REV1 expression differs in different tumour types. Low REV1 expression is associated with better prognosis in colorectal disease specific survival (DSS), disease-free survival (DFS), gastric overall survival (OS), post progression survival (PPS) and ovarian (OS, PPS) cancer while high REV1 expression is associated with better prognosis in lung [OS, relapse free survival (RFS), first progession (FP), PPS] and breast (DSS, RFS) cancer. In colon adenocarcinoma and rectum adenocarcinoma and lung adenocarcinoma, low expression of REV1 may suggest resistance to drugs in certain pathways. Conversely, high expression of REV1 in acute myeloid leukemia, brain lower grade glioma, small cell lung cancer and thyroid carcinoma may indicate resistance to drugs in certain pathways.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> REV1 plays different roles in different tumor types, drug susceptibility, and related biological events. REV1 expression is significantly correlated with different prognosis in colorectal, ovarian, lung, breast, and gastric cancer. REV1 expression can be used as predictive marker for various drugs of various pathways in different tumors.<\/jats:p>","DOI":"10.3389\/fgene.2022.997970","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T13:16:24Z","timestamp":1664457384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["REV1: A novel biomarker and potential therapeutic target for various cancers"],"prefix":"10.3389","volume":"13","author":[{"given":"Ning","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yier","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/1541-7786.MCR-08-0399","article-title":"REV1 is implicated in the development of carcinogen-induced lung cancer","volume":"7","author":"Dumstorf","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/cr.2007.117","article-title":"DNA polymerase zeta (pol zeta) in higher eukaryotes","volume":"18","author":"Gan","year":"2008","journal-title":"Cell Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2217\/pgs.14.14","article-title":"Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma","volume":"15","author":"Goricar","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/omi.2014.0159","article-title":"Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients","volume":"19","author":"Goricar","year":"2015","journal-title":"Omics a J. Integr. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.1093\/emboj\/cdg626","article-title":"Mouse Rev1 protein interacts with multiple DNA polymerases involved in translesion DNA synthesis","volume":"22","author":"Guo","year":"2003","journal-title":"EMBO J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10654-008-9251-5","article-title":"REV1 genetic variants associated with the risk of cervical carcinoma","volume":"23","author":"He","year":"2008","journal-title":"Eur. J. Epidemiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.3390\/cancers13215290","article-title":"REV1 inhibition enhances radioresistance and autophagy","volume":"13","author":"Ikeh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1568-7864(02)00038-1","article-title":"Cellular roles of DNA polymerase zeta and Rev1 protein","volume":"1","author":"Lawrence","year":"2002","journal-title":"DNA Repair"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1124\/mol.105.020446","article-title":"Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells","volume":"69","author":"Lin","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/bioinformatics\/btv362","article-title":"IBS: an illustrator for the presentation and visualization of biological sequences","volume":"31","author":"Liu","year":"2015","journal-title":"Bioinformatics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"35644","DOI":"10.1074\/jbc.M102051200","article-title":"Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7","volume":"276","author":"Murakumo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1126\/science.1116336","article-title":"Rev1 employs a novel mechanism of DNA synthesis using a protein template","volume":"309","author":"Nair","year":"2005","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"eaaz7808","DOI":"10.1126\/sciadv.aaz7808","article-title":"Inhibition of the translesion synthesis polymerase REV1 exploits replication gaps as a cancer vulnerability","volume":"6","author":"Nayak","year":"2020","journal-title":"Sci. Adv."},{"key":"B14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1356-9597.2004.00747.x","article-title":"Interaction of hREV1 with three human Y-family DNA polymerases","volume":"9","author":"Ohashi","year":"2004","journal-title":"Genes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1124\/mol.104.010579","article-title":"Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin","volume":"67","author":"Okuda","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/molecules27030636","article-title":"Disrupting the MAD2L2-rev1 complex enhances cell death upon DNA damage","volume":"27","author":"Pernicone","year":"2022","journal-title":"Mol. (Basel, Switz)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1021\/bi300566z","article-title":"NMR structure and dynamics of the C-terminal domain from human Rev1 and its complex with Rev1 interacting region of DNA polymerase \u03b7.","volume":"51","author":"Pozhidaeva","year":"2012","journal-title":"Biochemistry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.dnarep.2013.12.005","article-title":"Gap-filling and bypass at the replication fork are both active mechanisms for tolerance of low-dose ultraviolet-induced DNA damage in the human genome","volume":"14","author":"Quinet","year":"2014","journal-title":"DNA Repair"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1021\/acschembio.6b01144","article-title":"Identification of small molecule translesion synthesis inhibitors that target the rev1-CT\/RIR protein-protein interaction","volume":"12","author":"Sail","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ijc.20790","article-title":"Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk","volume":"114","author":"Sakiyama","year":"2005","journal-title":"Int. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"a012708","DOI":"10.1101\/cshperspect.a012708","article-title":"Translesion DNA synthesis and mutagenesis in eukaryotes","volume":"5","author":"Sale","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/carcin\/bgw208","article-title":"Overexpression of Rev1 promotes the development of carcinogen-induced intestinal adenomas via accumulation of point mutation and suppression of apoptosis proportionally to the Rev1 expression level","volume":"38","author":"Sasatani","year":"2017","journal-title":"Carcinogenesis"},{"key":"B23","first-page":"201","article-title":"The role of DNA adducts in smoking-related carcinogenesis","volume":"48","author":"Schoket","year":"2004","journal-title":"Magy. Onkol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jmb.2009.05.026","article-title":"Structure of the human Rev1-DNA-dNTP ternary complex","volume":"390","author":"Swan","year":"2009","journal-title":"J. Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1016\/j.molcel.2021.09.013","article-title":"Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells","volume":"81","author":"Tirman","year":"2021","journal-title":"Mol. Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.dnarep.2004.06.015","article-title":"Co-localization in replication foci and interaction of human Y-family members, DNA polymerase pol eta and REVl protein","volume":"3","author":"Tissier","year":"2004","journal-title":"DNA Repair"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1016\/j.jmb.2018.05.042","article-title":"Structures of REV1 UBM2 domain complex with ubiquitin and with a small-molecule that inhibits the REV1 UBM2-ubiquitin interaction","volume":"430","author":"Vanarotti","year":"2018","journal-title":"J. Mol. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-011-1460-z","article-title":"Genetic variation in genes encoding for polymerase zeta subunits associates with breast cancer risk, tumour characteristics and survival","volume":"129","author":"Varadi","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/1471-2105-11-548","article-title":"Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces","volume":"11","author":"Venselaar","year":"2010","journal-title":"BMC Bioinforma."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1158\/0008-5472.CAN-12-0103","article-title":"MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.bbapap.2009.07.004","article-title":"Variations on a theme: eukaryotic Y-family DNA polymerases","volume":"1804","author":"Washington","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1128\/MMBR.00034-08","article-title":"Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance","volume":"73","author":"Waters","year":"2009","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"26400","DOI":"10.1074\/jbc.M112.380998","article-title":"Multifaceted recognition of vertebrate Rev1 by translesion polymerases \u03b6 and \u03ba","volume":"287","author":"Wojtaszek","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cell.2019.05.028","article-title":"A small molecule targeting mutagenic translesion synthesis improves chemotherapy","volume":"178","author":"Wojtaszek","year":"2019","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20792","DOI":"10.1073\/pnas.1011412107","article-title":"Error-prone translesion synthesis mediates acquired chemoresistance","volume":"107","author":"Xie","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.canep.2013.08.003","article-title":"Effects of polymorphisms in translesion DNA synthesis genes on lung cancer risk and prognosis in Chinese men","volume":"37","author":"Xu","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1006842","DOI":"10.1371\/journal.pgen.1006842","article-title":"Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?","volume":"13","author":"Yamanaka","year":"2017","journal-title":"PLoS Genet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1093\/nar\/gkv737","article-title":"FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1021\/acs.chemrestox.5b00513","article-title":"Effects of twelve germline missense variations on DNA lesion and G-quadruplex bypass activities of human DNA polymerase REV1","volume":"29","author":"Yeom","year":"2016","journal-title":"Chem. Res. Toxicol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.997970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T13:16:29Z","timestamp":1664457389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.997970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":40,"alternative-id":["10.3389\/fgene.2022.997970"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.997970","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"997970"}}